Fiberside Chat: Choosing the Right Software Solution for a Streamlined Digital Transformation

 

When it comes time for telcos to pick a software solution to streamline or transform their digital transformation, the decision boils down to this question: Do they select a commercial off the shelf (COTS) software or a custom solution? 3-GISKevin Noack, Director of Information Systems, and David Stoner, Director of Product Development, shared their perspectives and insights.

“I think it’s a convergence of the digital transformation and GIS, and with the off the shelf solution, not only are you getting digital…you’re also in a common communication platform,” Noack said. “ You don’t want to be in some proprietary custom solution that you can’t get your data out and share easily or share versions of it to do different entities.” Nor do you want to be stuck with a system that doesn’t match with your unique operating and service-differentiating workflows.

So, how does a telco decide on the right option? One of the primary value points for a COTS solution is in-software maintenance and support. Another long view consideration is the configurability of the COTS software. That is the ability for the system administrators to change the configuration for user sets, workflows, UI metaphors, etc. rather than having to incur additional costs for programming changes.

“Having a COTS solution allows various departments to have various access points into the application without having to do a different customized version for each department,” Noack continued.

“Really when it gets down to it, when an end user is using a system, they want it to look and feel customized for their job function. And through configuration, we really can control the look and feel and down to the workflow level for that individual group,” Stoner added. “That’s very powerful…you think about a team of disparate user bases using the same central platform to get their job done and being able to provide that custom feel without the custom application code makes a big difference.”

Be sure to subscribe to our industry publication for the latest news, videos, and podcasts in the Software & Technology Industry.

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Follow us on social media for the latest updates in B2B!

Image

Latest

vitro
Analyzing the Suppressive TME in In Vitro Based Assays
April 19, 2025

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

Read More
cancer
Targeting T Cells Within the Cancer Immunity Cycle
April 19, 2025

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

Read More
cancer Immunity cycle
Advanced In Vitro Technologies to Investigate Therapeutic Impact on the Cancer Immunity Cycle
April 19, 2025

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…

Read More
resistance
Inside Oncology Drug Development: Overcoming Resistance with Science
April 19, 2025

In the last two decades, oncology has undergone a transformation with over 300 new cancer therapies approved by the FDA—many offering novel mechanisms of action. Despite these innovations, resistance to treatment remains a critical challenge, with cancer cells evolving or adapting to evade even the most advanced therapeutics. This issue is particularly pressing given that…

Read More